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Abstract
The present study was conducted to explore whether single nucleotide polymorphisms (SNPs) in Th1 and Th17 cell-
mediated immune response genes differentially influence the risk of rheumatoid arthritis (RA) in women and men. In phase
one, 27 functional/tagging polymorphisms in C-type lectins and MCP-1/CCR2 axis were genotyped in 458 RA patients and
512 controls. Carriers of Dectin-2rs4264222T allele had an increased risk of RA (OR = 1.47, 95%CI 1.10–1.96) whereas patients
harboring the DC-SIGNrs4804803G, MCP-1rs1024611G, MCP-1rs13900T and MCP-1rs4586C alleles had a decreased risk of developing
the disease (OR = 0.66, 95%CI 0.49–0.88; OR = 0.66, 95%CI 0.50–0.89; OR = 0.73, 95%CI 0.55–0.97 and OR = 0.68, 95%CI 0.51–
0.91). Interestingly, significant gender-specific differences were observed for Dectin-2rs4264222 and Dectin-2rs7134303: women
carrying the Dectin-2rs4264222T and Dectin-2rs7134303G alleles had an increased risk of RA (OR = 1.93, 95%CI 1.34–2.79 and
OR = 1.90, 95%CI 1.29–2.80). Also five other SNPs showed significant associations only with one gender: women carrying the
MCP-1rs1024611G, MCP-1rs13900T and MCP-1rs4586C alleles had a decreased risk of RA (OR = 0.61, 95%CI 0.43–0.87; OR = 0.67,
95%CI 0.47–0.95 and OR = 0.60, 95%CI 0.42–0.86). In men, carriers of the DC-SIGNrs2287886A allele had an increased risk of RA
(OR = 1.70, 95%CI 1.03–2.78), whereas carriers of the DC-SIGNrs4804803G had a decreased risk of developing the disease
(OR = 0.53, 95%CI 0.32–0.89). In phase 2, we genotyped these SNPs in 754 RA patients and 519 controls, leading to
consistent gender-specific associations for Dectin-2rs4264222, MCP-1rs1024611, MCP-1rs13900 and DC-SIGNrs4804803 polymorphisms
in the pooled sample (OR = 1.38, 95%CI 1.08–1.77; OR = 0.74, 95%CI 0.58–0.94; OR = 0.76, 95%CI 0.59–0.97 and OR = 0.56,
95%CI 0.34–0.93). SNP-SNP interaction analysis of significant SNPs also showed a significant two-locus interaction model in
women that was not seen in men. This model consisted of Dectin-2rs4264222 and Dectin-2rs7134303 SNPs and suggested a
synergistic effect between the variants. These findings suggest that Dectin-2, MCP-1 and DC-SIGN polymorphisms may, at
least in part, account for gender-associated differences in susceptibility to RA.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by chronic inflammatory activity in the synovial joints often
leading to progressive cartilage and bone destruction [1]. Although
etiology of RA is still unknown, it has been suggested that activated
macrophages and dendritic cells (DCs), rather than T-cells, may be
important for the onset of the disease. In the RA synovium,
macrophages mature into tissue macrophages and differentiate
into DCs leading to massive release of a wide number of pro-
inflammatory mediators [2–4] and to the induction of adhesion
(C-type lectins) and co-stimulatory molecules (CD40, CD80,
CD86) that participate in the activated macrophage- and DC-
induced T-cell proliferation [5,6]. Among all these immune
mediators, MCP-1/CCL2, a chemokine highly expressed in the
synovial fluid of RA patients [7], binds to CCR2 and promotes the
recruitment of antigen-presenting cells and T cells [8] whereas C-
type lectins such as Dectin-1, Dectin-2 and DC-SIGN regulate the
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monocyte-induced T-cell activation in the RA synovium [5,6]. C-
type lectins also modulate adaptive immune responses, of which
especially Th17 responses are implicated in the stimulation of
osteoclastogenesis and bone destruction during RA [9].
RA is three times more frequent in women than men [10] and
emerging data also suggest that women are more likely to present a
worse course of the disease and to become severely disabled
[11,12]. Although different hypotheses concerning sex-related
differences in RA incidence and severity have been generated, the
hypothesis suggesting a sexual dimorphism in the intensity of
immune responses remains as one of the most probable
mechanisms in promoting and establishing a different synovial
membrane inflammation and, subsequently, different levels of
cartilage and bone erosion [13,14]. Women have higher immu-
noglobulin levels than men, they show stronger Th1-type cell-
mediated immune responses and they have higher absolute
numbers of CD4+ lymphocytes and a more proactive cytokine
profile [15,16], which likely contribute to their increased
autoimmune responses [17]. Experimental studies in rodents have
also shown different immune responses between female and male
animals and an equivalent sexual dimorphism in the incidence of
RA [18]. The underlying reasons for this gender bias are still
unknown, but studies in monozygotic twins have suggested that
genetic factors may, at least in part, account for sex-related
differences in the immune responses [19] and, consequently, in the
susceptibility to autoimmune diseases. Genetic factors implicated
in RA have been widely studied using both candidate genes [20]
and whole-genome screens [21] but, so far, only a few studies have
investigated the link between SNPs and the gender-associated
differences in susceptibility to RA [22,23]. Considering these facts,
the present study was designed to evaluate the influence of 27
tagging and potentially functional SNPs within the MCP-1, CCR2,
DC-SIGN, Dectin-1, and Dectin-2 genes in the risk to develop RA in
women and men, separately.
Materials and Methods
Study Population
In phase 1, all participants enrolled were Caucasian and
recruited at the department of Rheumatology of the Virgen de las
Nieves (Granada, Spain) and Reina Sofia (Córdoba, Spain)
hospitals. All participants gave their written informed consent to
participate in the study, which was approved by the ethical review
committee of participant institutions (Virgen de las Nieves
University Hospital, Granada, Spain; Reina Sofia Hospital,
Córdoba, Spain). The study was performed according to the
principles of the Declaration of Helsinki. The population consisted
of 970 participants, 458 RA patients (360 women and 98 men) and
512 healthy controls (217 women and 295 men). Rheumatoid
patients were treated at their respective departments of Rheuma-
tology from January 2004 to January 2010. The diagnosis of RA
was assigned by physician investigators and fulfilled the 1987
American College of Rheumatology (ACR) criteria. We chose
DAS28 as a measure of disease activity as it is a validated score for
established RA. Moderate to high activity disease was defined as
DAS28$3.2 while low disease activity was defined as
DAS28,3.2. Controls were blood donor subjects randomly
recruited at the Regional Blood Transfusion and Tissue Centre
(Granada-Almerı́a, Spain).
In phase 2, in order to increase the statistical power of the study
and confirm both overall and gender-specific associations, we
extended the study by recruiting additional RA cases (n = 831) and
controls (n = 550) from our own institution as well as from other
collaborating institutions. Seven hundred and seventy-three RA
patients and 201 controls were recruited from the Santa Maria
Hospital–CHLN (Lisbon, Portugal). Fifty-eight additional RA
patients were recruited from the University Clinical Hospital of
Santiago de Compostela (Santiago de Compostela, Spain). We also
recruited 349 healthy controls from our own institution (Virgen de
las Nieves University hospital, Granada, Spain; n = 260) as well as
from the Reina Sofı́a hospital (Córdoba, Spain; n = 89). All
participants gave their written informed consent to participate in
the study, which was approved by the respective ethical review
committee of participant institutions. Thirty-four non-Caucasian
subjects were excluded from the statistical analyses (n = 34) and
some additional patients and controls were also removed for
technical reasons (low DNA quality, unknown age or gender, etc.).
Seven hundred and fifty-four RA patients (626 women and 128
men) and 519 healthy controls (348 women and 171 men) were
finally available for genotyping.
SNP Selection and Genotyping
Twenty-seven tagging/functional SNPs within DC-SIGN, Dectin-
1, Dectin-2, MCP-1 and CCR2 were selected to genotype the entire
panel of individuals (Table 1; Supplementary material). The aim
of the SNP tagging was to identify a set of SNPs that efficiently tags
all the known SNPs while the functional approach was used to
determine the net impact of potentially functional variants within
DC-SIGN, Dectin-1, Dectin-2, MCP-1 and CCR2 genes on RA risk.
Tagging SNPs were selected using Haploview Tagger program
(http://www.broad.mit.edu/mpg/haploview/; http://www.
broad.mit.edu/mpg/tagger/). SNPs with a MAF.0.05 were
included in the selection of tag SNPs using a pairwise tagging
with a minimum r2 of 0.8. In this selection we forced the inclusion
of the DC-SIGNrs4804803, MCP-1rs1024610 and MCP-1rs1024611
polymorphisms as their functionality has been suggested [24–
26]. One extra SNP within DC-SIGN (rs11465384) and in strong
linkage disequilibrium (LD) with at least 4 SNPs was selected as
redundant SNP in case of genotyping failure. Genomic DNA was
extracted from peripheral blood mononuclear cells (PBMCs) using
Qiagen Mini Kit (Qiagen, Valencia, CA, USA). Genotyping of
DC-SIGN, Dectin-1, Dectin-2, MCP-1 and CCR2 polymorphisms was
carried out using allele-specific KASParH assays (LGC Genomics
KBioscience, London, United Kingdom) in a 384-well plate
format (Applied Biosystems, Foster City, CA, USA) where
population samples (RA and healthy controls) were randomly
distributed. KASPar reactions were performed using KASPar
assay mix (containing probes) and KASPar kit containing 2X
Reaction Mix and MgCl2 (50 mM). Touch-down PCR conditions
were: denaturation at 94uC for 15 min, 10 cycles of denaturation
at 94uC for 20 sec, annealing at 61uC for 60 sec (dropping –0.6uC
per cycle) and 26 cycles of denaturation at 94uC for 10 sec,
annealing at 55uC for 60 sec. Recycling conditions were 94uC for
10 sec, annealing and elongation at 60uC for 60 sec. PCR
products were analyzed with the ABI Prism 7900HT detection
system using the SDS 2.4 software (Applied Biosystems). For
internal quality control, 5% of samples were randomly selected
and included as duplicate. Concordance between the original and
the duplicate samples for the 27 SNPs analyzed was $99.0%. Call
rates for all SNPs were $95.0% with the exception of the Dectin-
1rs11053599 SNP with a call rate ,90.0%. This latter SNP was
excluded from further analysis.
Statistical Analysis
The Hardy-Weinberg Equilibrium (HWE) tests were performed
in the control group by a standard observed-expected chi-square
(x2) test at each polymorphic site (http://ihg2.helmholtz-
muenchen.de/cgi-bin/hw/hwa1.pl). Binary logistic regression
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was used to assess the main effects of the genetic polymorphisms
on RA risk using co-dominant and dominant inheritance models.
For each SNP, the more common allele in the control group was
assigned as the reference category. Binary logistic regression
analyses were adjusted for age and gender whereas gender-
stratified analyses were adjusted for age. In the pooled analysis,
overall binary logistic regression analyses were adjusted by age,
gender and centre whereas gender-stratified analyses were
adjusted for age and centre. Statistical power was estimated using
Quanto software (http://hydra.usc.edu/gxe/). All analyses were
conducted using the statistical software SSPS (version 14.0, SPSS
Inc., Chicago, USA). All tests were considered to be statistically
significant when p,0.05. In order to correct for multiple testing,
we calculated an adjusted significance level using Meff correction.
We estimated an individual Meff value for each gene (i.e. the
effective number of independent variables) and the study-wise Meff
value was estimated by adding up the independent gene Meff
values by using the SNP Spectral Decomposition Lite program
(http://gump.qimr.edu.au/general/daleN/SNPSpDsuperlite/)
[27]. The resulting number of independent marker loci was
applied to correct for multiple testing.
Functional Prediction of Associated SNPs
We used a web-based tool FastSNP (available at http://fastsnp.
ibms.sinica.edu.tw) for predicting the functional significance of the
SNPs associated with RA. A detailed explanation on the FastSNP
tool has been described elsewhere [28]. FastSNP utilizes
information from different web resources (Hapmap, dbSNP,
NCBI Blast, Polyphen, SNPs3D, TRANSFAC, ESEfinder,
Rescue-ESE and FAS-ESS) to determine whether SNPs are
located at exonic splicing regulatory sites or whether they alter the
transcription factor-binding site of a gene (for instance, acting as
intronic enhancer) or even whether SNPs are affecting Micro-
RNA binding sites. In addition, these tools are able to identify
either nonsense or non-synonymous SNPs that lead to premature
termination of translation or amino acid changes and that are,
therefore, very likely to affect protein function.
SNP-SNP Interaction Analysis
We also analyzed high-order interactions between significant
SNPs using the multifactor dimensionality reduction (MDR)
constructive induction algorithm. A detailed explanation on the
MDR method has been described elsewhere [29]. Cross-validation
and permutation testing were used to identify the best models. All
possible two-way SNP interactions were tested using 10-fold cross-
validation and the exhaustive search. The model with the highest
testing balanced accuracy (TA) and cross validation consistency
(CVC) was selected as ‘‘best model’’. Statistical significance was
evaluated by the Sign test and confirmed using a 1.000-fold
permutation test to compare observed testing balanced accuracies
with those expected under the null hypothesis of no association
(using the MDR permutation testing module 0.4.9 alpha) [29].
MDR results were considered statistically significant at the level of
0.05. MDR software and MDR permutation testing module are
open-source and freely available from http://www.epistasis.org.
Logistic regression analyses were also performed to confirm
significant interaction results from MDR analyses.
Results
Demographic and clinical characteristics of the RA patients
analysed in phase 1 are described in Table 2. Controls were
slightly younger than RA patients (53.4669.69 vs. 58.51613.13;
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70.7% were positive for anti-CCP antibodies and 71.2% were
positive for RF (rheumatoid factor). According to the DAS28,
male patients showed low active disease (DAS28Male = 2.89)
whereas women had moderately active disease (DAS28Fe-
male = 3.42). Women tended to have more often a DAS28$3.2
compared to men (56.18% vs. 43.48%, p = 0.078). The overall
average disease duration was 12.39 years.
All analyzed SNPs were in HWE in the control group with the
exception of Dectin-1rs16910631 (p.0.01). Five SNPs showed overall
association with RA (Table 3 and Table S1). Carriers of Dectin-
2rs4264222T allele had an increased risk of RA (OR = 1.47, 95%CI
1.10–1.96, P = 0.009) whereas patients harboring the DC-
SIGNrs4804803G, MCP-1rs1024611G, MCP-1rs13900T and MCP-
1rs4586C alleles had a decreased risk of developing the disease
(OR = 0.66, 95%CI 0.49–0.88, P = 0.004; OR = 0.66, 95%CI
0.50–0.89, P = 0.006; OR = 0.73, 95%CI 0.55–0.97, P = 0.03 and
OR = 0.68, 95%CI 0.51–0.91, P = 0.009; Table 3). In addition,
patients bearing the Dectin-2rs7134303G allele showed a trend to have
an increased risk for RA (OR = 1.35, 95%CI 1.00–1.83). Most
importantly, binary logistic regression analyses revealed gender-
specific associations with RA for six SNPs (Table 3). There was a
significant effect modification by gender for Dectin-2rs4264222 and
Dectin-2rs7134303 SNPs (Pinteraction = 0.041 and 0.011, respectively;
Table 3). Women carrying either the Dectin-2rs4264222T or Dectin-
2rs7134303G alleles had an increased risk of RA (OR = 1.93, 95%CI
1.34–2.79 and OR = 1.90, 95%CI 1.29–2.80). Additionally,
women carrying the MCP-1rs1024611G, MCP-1rs13900T and MCP-
1rs4586C alleles had a decreased risk of RA compared with those
carrying the wild-type genotype (OR = 0.61, 95%CI 0.43–0.87;
OR = 0.67, 95%CI 0.47–0.95 and OR = 0.60, 95%CI 0.42–0.86).
As also men had decreased, but statistically not significant ORs, no
effect modification by gender was observed. A borderline gender-
specific effect was observed for the DC-SIGNrs2287886 SNP
(Pinteraction = 0.071; Table 3). Here, male carriers of the DC-
SIGNrs2287886A allele had an increased risk of RA (OR = 1.70,
95%CI 1.03–2.78). Additionally, the association of the DC-
SIGNrs4804803G with a decreased risk was stronger in men than in
women (OR = 0.53, 95%CI 0.32–0.89 vs. OR = 0.73, 95%CI
0.51–1.04).
After correction for multiple testing using the SNP Spectral
Decomposition Lite program (number of independent marker loci,
21; p = 0.05/21 = 0.002), only the Dectin-2rs4264222 and Dectin-
Table 2. Demographic and clinical characteristics of RA patients.
RA patients
Overall (n = 458) Women (n = 360) Men (n = 98)
Demographic characteristics
Age (years) 58.51613.13 57.94613.02 60.56613.39
Clinical assessment
Disease duration (years) 12.3967.62 12.6467.84 11.4366.61
Percentage of patients with RF positivity 71.20 70.26 74.72
Percentage of patients with positive anti-CCP * 70.70 71.65 66.67
Current DAS28 (average) 3.31 3.42 2.89
Treatments
DMARDs
Methotrexate (%) 259 (56.55) 207 (57.50) 52 (53.06)
Leflunomide (%) 178 (38.86) 132 (36.67) 46 (46.94)
Sulphasalazine (%) 40 (8.73) 31 (8.61) 9 (9.18)
Biologic agents
Infliximab (%) 171 (37.34) 141 (39.17) 30 (30.61)
Etanercept (%) 140 (30.57) 116 (32.22) 24 (24.49)
Adalimumab (%) 124 (27.07) 102 (28.33) 22 (22.45)
Abatacept (%) 43 (9.39) 35 (9.72) 8 (8.16)
Rituximab (%) 112 (24.45) 91 (25.28) 21 (21.42)
Tocilimumab (%) 20 (4.37) 18 (5.00) 2 (2.04)
Others (%) 7 (1.52) 6 (1.67) 1 (1.02)
Number of biologic agents
0 114 (24.89) 76 (21.11) 38 (38.77)
1 195 (42.58) 162 (45.00) 33 (33.67)
2 71 (15.50) 56 (15.55) 15 (15.31)
3 46 (10.04) 40 (11.11) 6 (6.12)
4 20 (4.37) 17 (4.72) 3 (3.06)
.4 12 (2.62) 9 (2.50) 3 (3.06)
Data are means 6 standard deviation. Abbreviations: RF, rheumatoid factor; Anti-CCP: anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score;
DMARDs, disease-modifying antirheumatic drugs.
*Anti-CCP value was available only in 314 patients (254 women and 60 men).
doi:10.1371/journal.pone.0072732.t002
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2rs7134303 associations in women retained significance (P = 3.00 E-
04 and P = 9.00 E-04), whereas the associations with DC-
SIGNrs4804803, MCP-1rs1024611 and MCP-1rs4586 showed borderline
significance in the whole population (P = 0.004, P = 0.006 and
P = 0.009; Table 3).
In phase 2, in order to increase the statistical power of this study
and to confirm the significant associations, we further genotyped
the significant SNPs in 754 Caucasian RA patients (626 women
and 128 men) and 519 healthy controls (348 women and 171
men). Clinical characteristics of the RA patient population are
shown in Table S2 and characteristics of the pooled population are
shown in Table S3. In the phase 2, RA patients had a similar age
and showed slightly higher percentages of anti-CCP (77.72 vs.
70.70) and RF positivity (75.98 vs. 71.20). As before, male patients
showed low active disease when compared to women (DAS28-
Male = 3.21 vs. DAS28Female = 3.78). Thus, we end up with a total
population of 2.243 individuals including 1.212 RA patients (986
women and 226 men) and 1.031 controls (565 women and 466
men). After this recruitment the study had over 80% power (co-
dominant model) to detect an odds ratio of 1.19 at alpha = 0.008
(multiple testing threshold) for a polymorphism with a minor allele
frequency of 0.25. Although the gender-stratified analysis reduced
the statistical power of the study, we still had power to detect
reasonably small risks (ORWOMEN = 1.23 and ORMEN = 1.36).
Binary logistic regression analysis adjusted for age, gender and
center in the pooled population showed that MCP-1rs1024611, MCP-
1rs13900, MCP-1rs4586 and DC-SIGNrs4804803 polymorphisms were
associated with a decreased risk of developing RA (OR = 0.76,
95%CI 0.61–0.95, P = 0.01; OR = 0.77, 95%CI 0.62–0.96,
P = 0.02; OR = 0.80, 95%CI 0.64–0.99, P = 0.04; and
OR = 0.77, 95%CI 0.62–0.96, P = 0.02; Table 4). Although there
was no significant effect modification by gender, Dectin-2 and
MCP-1 polymorphisms seemed to have an stronger effect in
women compared to men, whereas variants within DC-SIGN
showed more evident effects in men. Thus, women carrying the
Dectin-2rs4264222T allele had an increased risk of RA (OR = 1.38,
95%CI 1.08–1.77, P = 0.01) whereas women harbouring the
MCP-1rs1024611G and MCP-1rs13900T alleles had a decreased risk of
RA in comparison with those carrying the wild-type genotype
(OR = 0.74, 95%CI 0.58–0.94, P = 0.02 and OR = 0.76, 95%CI
0.59–0.97, P = 0.03; Table 4). Women bearing the Dectin-
2rs7134303G showed also a trend towards an increased risk of the
disease (OR = 1.30, 95%CI 1.00–1.69, P = 0.05) whereas those
women carrying the MCP-1rs4586C allele had a decreased risk for
RA (OR = 0.78, 95%CI 0.61–1.00, P = 0.05; Table 4). We could
confirm that none of these effects was observed in men. We also
confirmed that men carrying the DC-SIGNrs4804803G allele had a
decreased risk to develop RA (OR = 0.56, 95%CI 0.34–0.93,
P = 0.02; Table 4) whereas men harboring DC-SIGNrs2287886A
allele had trend to have an increased risk of RA (OR = 1.54,
95%CI 0.96–2.46, P = 0.07). None of these associations resisted
multiple testing adjustments in the pooled sample (number of
independent marker loci was estimated including only those SNPs
genotyped in the pooled sample; p = 0.05/6 = 0.008) and all
require further replication in independent populations.
For predicting the effect of polymorphisms found associated
with RA we used FastSNP, which predicts the possible effect of
genetic variants on the protein function and/or structure. Among
the SNPs associated either with increased or decreased risk of RA,
2 SNPs were predicted to have functional impact. The predictive
functional analysis suggested an intronic enhancer function for
Dectin-2rs7134303 due to its location in a transcription factor-binding
site (risk score 1–2) and a function as gene expression regulator for
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2rs7134303G allele creates a nuclear protein-binding site for the
transcription factor GATA-1 (GATA-binding factor 1) whereas
the presence of the MCP-1rs1024611T allele, which confers
protection against RA, disrupts a binding site for both GATA-1
and GATA-2 in the promoter region of the MCP-1 gene. Whereas
GATA-1 is a transcription factor expressed in circulating
inflammatory monocytes and indispensable for effective DC
maturation and survival, GATA-2 expression inhibits monocyte
differentiation. These data suggest a central role of the Dectin-
2rs7134303 and MCP-1rs1024611 polymorphisms in the gender-
associated susceptibility to RA and point out a possible participa-
tion of GATA-1 and GATA-2 in the modulation of Dectin-2 and
MCP-1 expression and, consequently, in the activation of both
monocytes and DCs.
We also investigated the epistatic effect of the significant SNPs
in order to find possible gender-specific high order interactions. A
summary of the results for the models that had maximum testing
accuracy and maximum cross validation consistency in women
and men is presented in Table 5. In women, the overall best model
consisted of Dectin-2rs4264222 and Dectin-2rs7134303 SNPs that
interacted in a synergistic or non-additive manner. Logistic
regression analysis applied to this two -locus model confirmed
our results (P = 0.007). In men, no SNP-SNP interactions were
shown to be significant (Table 5).
Finally, we explored the effect of selected SNPs on disease
activity and severity. No differences were found in relation to
DAS28, the positivity for anti-CCP antibodies or RF when RA
patients were grouped by gender and genotype (data not shown).
Discussion
The idea that genetic factors have an impact on the
predisposition to RA is well supported by our understanding of
the disease biology and by data from a wide range of genetic
epidemiologic studies [30–32]. This fact, along with studies
showing sex-specific differences in incidence of RA and in immune
response [10,33], suggests that genetic factors modulating the
immune response may contribute to the sex-specific incidence
rates. Considering this hypothesis, the present study was carried
out to assess whether genetic variants within immune-related genes
may differentially play a role in determining the risk of RA in
women and men. Although to date there have been too few studies
addressing the effect of gender on the risk of RA, some previous
studies have reported female-specific associations between genetic
variants in immune genes (TNF, TNFR2, IL4R and CD4) and risk
of RA [23,34,35].
The present population-based case-control study included 2.243
individuals (1.212 RA patients and 1.031 controls) and confirmed
the role of 4 SNPs within Dectin-2, MCP-1 and DC-SIGN genes in
determining the risk of RA. These results were in agreement with a
previous study performed by Platinga et al. (2010), who reported
no overall association of Dectin-1rs16910526 SNP with RA [36] but
were in contrast with those results described by Dieguez-González
et al. (2009) reporting no association of the DC-SIGNrs4804803 and
RA [37]. These controversial results might be attributed to
differences in population size and environmental factors but also
confounding factors such as gender.
We also identified, for the first time, genetic variants in Dectin-2,
DC-SIGN and MCP-1 as contributing to the gender-specific risk for
RA. Females with the Dectin-2rs4264222T allele had an increased risk
to develop RA whereas females carrying any of the MCP-
1rs1024611G and MCP-1rs13900T alleles had a decreased risk to
develop RA compared with carriers of the wild-type genotype. We
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have an increased risk of the disease whereas those women
carrying the MCP-1rs4586C allele showed a borderline significant
decreased risk for RA. In males, none of these effects were found
but carriers of the DC-SIGNrs4804803G had a significantly decreased
risk of developing the disease whereas those harboring the DC-
SIGNrs2287886A allele had trend to have an increased risk of RA.
Although there was not significant effect modification by gender,
Dectin-2, MCP-1 and DC-SIGN polymorphisms showed consistent
associations in women that were not seen in men and vice versa.
Of note is that, after adjusting the significance level to account for
multiple comparisons (study-wise significant P-threshold = 0.008),
Dectin-2rs4264222, MCP-1rs1024611, MCP-1rs13900 and MCP-1rs4586
SNPs showed both overall and gender-specific borderline signif-
icant associations. These results underlie the potential importance
of analyzing RA data both with and without gender as a stratifying
factor.
Gender-specific SNP-SNP interactions among the selected
variants indicated that the combined effect of the polymorphisms
with or without significant main effects conferred risk for RA. The
MDR approach used in this study identified a two-locus significant
model associated with high risk of RA in women while no
significant models were found in men. In women, the strongest
model for predicting RA risk was a model including Dectin-
2rs4264222 and Dectin-2rs7134303 SNPs that interact in synergistic
manner to increase the risk of RA. Although interesting, these
results should be interpreted with caution given that the statistical
modeling of SNP-SNP interactions may not be assumed as a true
biological interaction. However, based on in silico tools, hypotheses
concerning the molecular mechanisms resulting in differential
activity of genes can be created. In this regard, these two SNPs
(Dectin-2rs7134303 and Dectin-2rs4264222) were found to be important
in this study, both in the single SNP or the epistatic analysis. MDR
analysis was further confirmed by logistic regression analysis.
Dectin-2rs7134303 creates an allele-specific change in transcriptional
binding site for GATA-1 and could contribute, acting as intronic
enhancer, to the transcriptional regulation of Dectin-2 gene and,
consequently, to affect its intracellular signaling and downstream
gene expression.
According to these results, it is conceivable to suggest that
Dectin-2 variants, independently and/or through interactions may,
at least partially, account for gender differences in susceptibility to
RA. Dectin-2, a type II transmembrane receptor, is mainly
expressed in DCs, macrophages and B-cells and its expression
may be induced by inflammatory stimuli [38]. It is well known that
Dectin-2 recognizes carbohydrate motifs of self and non-self
antigens. However, it has also been suggested that Dectin-2 binds
to endogenous ligands in CD4+CD25+ [39] and CD8+ T-cells [40]
thus triggering inflammatory responses. Most recently, Dectin-2 has
been involved in promoting Syk- and CARD9-dependent NFkB
activation [41], inducing the expression of a wide variety of pro-
inflammatory mediators including cytokines, chemokines and co-
stimulatory molecules and, thereby enhancing T-cell mediated
immune responses. In line with this, Sato et al. also reported that,
contrary to Dectin-1 that binds Syk directly, Dectin-2 couples to Syk
through its association with Fc receptor gamma (FcRc) chain
leading to the activation of NFkB pathway and production of
cytokines such as TNF and IL1RA [42]. Interestingly, it has also
been described that Dectin-2 is involved in the modulation of Th17
immune responses and that the production of IL1b and IL23 upon
Dectin-2 requires c-Rel-dependent activation of NFkB [43]. These
findings, along with those suggesting the role of CD4+ T cells
secreting IL17 (Th17 cells) [44] and NFkB activation in the
pathogenesis and/or progression of RA [45], may indicate a key
role for Dectin-2 in the exacerbation of the immune response that
define the RA. Nonetheless, the molecular mechanisms by which
the Dectin-2rs7134303 and Dectin-2rs4264222 polymorphisms might
increase the risk for developing RA remain to be clarified. Based
on the findings reported by Gutierrez et al. (2007) that demonstrate
the expression of GATA-1 in circulating inflammatory monocytes
and its role in the maturation and survival of DCs [46] and given
our in silico predictions that the Dectin-2rs7134303_G allele might
create a binding site for this transcription factor, we might
hypothesize that this SNP could regulate Dectin-2 expression and,
consequently, to promote Dectin-2-induced NFkB activation and
production of cytokines such as TNF and IL1RA, the key molecules
in the ethiopathogenesis of RA. However, we cannot rule out the
possibility that Dectin-2rs7134303 and Dectin-2rs4264222 polymor-
phisms may be in linkage disequilibrium with unidentified
susceptible variants that are responsible for the significant
associations observed.
MCP-1/CCL2 is a modulator of monocyte/macrophage recruit-
ment to the site of inflammation and subsequent T-cell activation
[8] that acts through the CC chemokine receptor 2 (CCR2) [47].
MCP-1 is involved in the promotion of leukocyte infiltration
during the inflammation process and it has been found highly
expressed in the synovial fluid of RA patients [7]. Several
polymorphisms have been identified in the gene encoding MCP-
1 and some of them have previously been studied in relation to RA
susceptibility [48,49]. So far, most of these studies have been
focused only on a potentially functional SNP, the MCP-1rs1024611 (-
2518A/G) [24,25], but no association with RA was found in
Caucasian [48] or non-Caucasian populations [49,50]. Conversely
to these studies, we found an overall protective effect of the MCP-
1rs1024611, MCP-1rs13900 and MCP-1rs4586 polymorphisms on the
development of RA. However, given that the effect of these SNPs
was restricted to women and given that these previous studies were
Table 5. MDR analysis to detect two-locus disease models.
Women Gene Model TA Sing test (P-value) P-value* CVC
1 Dectin-2 rs7134303 0.5402 3 (P = 0.95) NS 9/10
2 Dectin-2 rs4264222, rs7134303 0.5560 8 (P = 0.05) 0.007 9/10
Men Gene Model TA Sing test (P-value) P-value* CVC
1 DC-SIGN rs2287886 0.5424 9 (P = 0.01) NS 10/10
2 MCP-1, DC-SIGN rs13900, rs2287886 0.4738 5 (P = 0.62) NS 3/10
TA, Testing accuracy; CVC, Cross-validation consistency. P,0.05 was considered significant. NS, not significant.
*P-value for testing balanced accuracy using 1.000-fold permutation test (MDR permutation testing module vs.0.4.9 alpha).
doi:10.1371/journal.pone.0072732.t005
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based on a small population size, these studies might not have had
sufficient statistical power to detect this association. Our predictive
functional analysis also revealed that MCP-1rs1024611 disrupts the
binding site for GATA-1 and GATA-2, which support our
hypothesis suggesting a central role of these transcription factors
mediating monocyte and DC maturation by controlling MCP-1
and Dectin-2 expression.
Similarly to other case-control studies, this study has several
potential limitations. First, the statistical power was limited when a
gender-stratified analysis was performed. To overcome this
problem, we reported dominant rather than only co-dominant
model. This limitation has also to be considered when analyzing
SNP-SNP interactions as the combined analysis reduced some
genotype groups to a few individuals. Finally, another limitation of
this study is that no in vivo mechanisms were clarified in relation to
Dectin-2, DC-SIGN and MCP-1 variants.
Conclusions
In conclusion, this study represents a preliminary step to
account for reported gender differences in RA incidence by
demonstrating that genetic polymorphisms within immune-related
genes may have different effects in women and men, hence
determining the way their immune systems respond to autoim-
mune stimuli. Nonetheless, further studies using independent
populations are warranted to validate our findings.
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